ABSTRACT
Introduction
Oral squamous cell carcinoma (OSCC) is a subgroup of oral and or pharyngeal squamous cell carcinomas (SCCs) and ranks the 11 th most common cancer in humans. It accounts for 2-3% of all malignancies and 94% of oral malignancies. It is characterized by poor prognosis and low survival rate. Despite recent advances in treatment of OSCC, survival rate of patients has only slightly increased in the past couple of decades (40% in the 1950s to 59% at present); thus, OSCC is hard to treat. [1] [2] [3] [4] [5] of tumoral cells and growth and metastasis of tumors.
[6] The association of angiogenesis and tumor growth has long been acknowledged, and it is believed that tumors derive their blood supply from the preexisting blood vessels. [7] Vascular endothelial growth factor is an important signaling protein that stimulates angiogenesis. [8] Evidence shows that the level of vascular endothelial growth factor (VEGF) in OSCC is much higher than that in normal tissues. [9] Moreover, it has been documented that level of VEGF in metastatic tumors is much higher than that in primary tumors.
Therefore, VEGF appears to be a critical factor for tumor growth and metastasis, and level of VEGF has a significant correlation with the stage of tumor and its progression. [9] Considering all the above, targeting an angiogenic factor such as VEGF may prevent tumor growth. years. Cha et al. [10] showed that TBZ decreased angiogenesis and vascular density by 50% in fibrosarcoma xenografts. Furthermore, they found that TBZ reversibly disassembled the newly formed blood vessels. Therefore, it may be suitable for use as a potential adjunct to the currently administered anti-angiogenic medications and chemotherapy drugs. Zhang et al. [9] also showed that TBZ inhibited angiogenesis in murine metastatic melanoma cell line B16F10 in vitro and in vivo via inhibiting the expression of vascular endothelial growth factor (VEGF) and inducing angiogenesis. In a recent study, Zhang et al. [11] optimized the structure of the lead compound of TBZ and obtained a new derivative, which they claimed to be over 100-fold more potent than the lead compound for inhibition of tumoral cell growth.
However, OSCC tumoral cells are more resistant to treatment and are less angiogenesis-dependent compared to other tumors. [12] [13] thus, the efficacy of TBZ for inhibition of growth of OSCC is a matter of question. To the best of authors' knowledge, the antiangiogenic effects of TBZ on OSCC cell line have not been previously investigated. Considering the availability and affordability of this drug, this study sought to assess the cytotoxic effects of different concentrations of TBZ on HN5 head and neck SCC cell line.
The effects of different concentrations of TBZ on expression and transcription of VEGF mRNA were also evaluated.
Materials and Method
This in vitro experimental study was conducted on HN5 SCC cell line.
Cell culture
The HN5 SCC cell line (code CI96) was obtained from The HN5 cells were cultured in RPMI-1640 (Gibco, Germany) culture medium supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 U/mL streptomycin and incubated at 37°C and 5% TBZ, cancer cells exposed to 400μM TBZ and cancer cells exposed to 550μM TBZ. Thus, extraction was performed separately for each group. Briefly, cell mass was lysed by the solution provided in the kit. The lysate was homogenized using a 5cc syringe, ethanol was added and the lysate and possibly the precipitate were transferred to the column for RNA adhesion to the column.
The column was washed to exclude excess material.
The extracted RNA was eluted and quantified qualitatively and qualitatively using NanoDrop (Thermo Fisher Scientific, MA, USA). This method provides OD at 260nm and 280nm and the ratio of OD at 260/280nm wavelength must be approximately 1.8 to 2.
cDNA synthesis cDNA was synthesized using Viva2-step RT-PCR kit (Cat No. RTPL12; Qiagen, Germany). The RT Primer
Mix provided in the kit contained the components required for reverse transcription.
Designing specific primers
Specific primers for each marker were designed and ordered for synthesis using AlleleID7 software. The synthesized primers (Gene Fanavaran Company; Tehran, Iran) in the form of lyophilized powder were dissolved in autoclave-sterilized distilled water and entered into the final reaction. Table 1 shows the characteristics of the primers used in real-time RT-PCR reaction.
Conduction of real-time RT-PCR using EvaGreenHotTaqqPCR

Mix
Sina clone kit (Cat No. BT11101; Qiagen, Germany) 20 20 Initiator R ATCTGCATGGTGATG TTGGA CCATCCAATCGGTAGTAGCG Primer length 20 20 Segment length The mean percentage of cell viability at different concentrations in the three time points is presented in Table 2 . Table 3 . 
Discussion
The anti-angiogenic and growth inhibition effects of Zhang et al. [9] showed that increase in drug concentra- evaluated in another study [16] and it was shown that after 27 days of treatment with 50mg/kg TBZ (equal to 250mg/kg), size of fibrosarcoma tumor in the test group decreased by more than 50% compared to that in controls.
Zhang et al. [9] showed that in the B16F10-bearing mice model, 100-400μM concentrations of TBZ (20, 40 , 80mg/kg) caused 16.5%, 35.4% and 48.7% reduction in tumor growth, respectively. The concentrations of TBZ used by Zhang et al. [9] on melanoma were higher than concentrations used by Cha et al. [10] on fibrosarcoma. This increase in concentration can be explained by the fact that fibrosarcoma is a mesenchymal tumor that contains numerous blood vessels. [17] Thus, it is more dependent on angiogenesis than melanoma and consequently, fibrosarcoma is more susceptible to anti-angiogenic drugs like TBZ. Based on this theory, it is speculated that since OSCC is resistant to treatment and less dependent on angiogenesis, [18] higher concentrations of TBZ will be probably required for inhibition of tumor growth and proliferation of tumoral cells in animal models. The mechanism of action of TBZ is not well understood. However, it has been shown that this drug inhibits fumarate reductase and results in cell death as such. [10] Comparison of the results of real time PCR of B16F10 cells in the study by Zhang et al. [9] and HN5 cells in the current study reveals that VEGF mRNA expression in B16F10 cells significantly decreased in presence of 300 and 500μM concentrations of TBZ compared to the control group. However, in our study, significant reduction in VEGF mRNA expression in HN5 cells was noted in presence of 400 and 550μM
concentrations of TBZ compared to the control group.
Inhibition of VEGF mRNA expression by higher concentrations of TBZ in our study compared to that of Zhang et al. [9] further confirms that head and neck tumors are less dependent on angiogenesis compared to tumors like melanoma, which are highly angiogenesisdependent. This finding has been reported in previous studies as well. [19] [20] The results of ELISA showed that TBZ inhibited the production of VEGF protein in a dose-dependent manner. In presence of 300μM concentration of TBZ, level of VEGF decreased by more than 50% (840ng/L) of its level in zero concentration of TBZ (2942mg/L). In presence of 550μM, level of VEGF reached to 283ng/L, which was one-tenth of its baseline level. Real-time PCR revealed that level of VEGF mRNA expression in presence of 300μM concentration of TBZ decreased by more than 50% of its value in the control group, which was equal to 10-fold change in its level.
Maximum safe dose of TBZ for administration in humans is 3g/day, which is equal to 50mg/kg (250μM) in a patient weighing 60kg. However, in our study, TBZ in 550μM concentration decreased the proliferation of HN5 cells by 50% at 48 hours. But, it should be noted that our study had an in vitro design and significant differences exist in drug pharmacokinetics in the human body and animals and in the culture medium with regard to protein-drug interactions, level of free drug, drug excretion, site of administration, and dose of administered drug at the target site. Thus, it should be kept in mind that effective concentration of drug in vitro is not equal to that in vivo since in the human body, part of the administered drug binds to plasma proteins and only free drug can affect cells.
To convert the IC50 dose of a drug in vitro to its equivalent in vivo, the above-mentioned pharmacokinetic properties must be evaluated in animal studies and then the required dose to reach the desired concentration of drug in vivo can be estimated. Another technique, which is based on try and error, is that the IC50 concentration in vitro can be injected to animal models to as- 
